Christian Ellebæk Elling
Director/Board Member bei IO BIOTECH, INC.
Vermögen: - $ am 31.03.2024
Profil
Christian Ellebæk Elling is the founder and currently holds multiple director positions.
He founded 7TM A in 2000 and currently serves as the Chief Executive Officer & Director.
He is also a Director at IO Biotech ApS, NMD Pharma A, and AFYX Therapeutics AS.
In addition, he is an Independent Director at IO Biotech, Inc. since 2015 and a Managing Partner at Lundbeckfonden Emerge since 2012.
Dr. Elling has previously held the position of Chief Executive Officer at Insusense ApS and Director at EpiTherapeutics ApS and Inagen ApS.
He holds a doctorate degree from the University of Copenhagen.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
IO BIOTECH, INC.
-.--% | 08.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Christian Ellebæk Elling
Unternehmen | Position | Beginn |
---|---|---|
IO BIOTECH, INC. | Director/Board Member | 01.12.2015 |
7TM A/S
7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Founder | 19.10.2009 |
Lundbeckfonden Emerge
Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark. | Private Equity Investor | 01.03.2012 |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Director/Board Member | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Director/Board Member | - |
AFYX Therapeutics AS
AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Director/Board Member | - |
Ehemalige bekannte Positionen von Christian Ellebæk Elling
Unternehmen | Position | Ende |
---|---|---|
Insusense ApS
Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | Chief Executive Officer | 01.10.2018 |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Director/Board Member | - |
Inagen ApS
Inagen ApS Miscellaneous Commercial ServicesCommercial Services Inagen ApS is a holding company that develops novel biopharmaceuticals for anti-viral treatment opportunities. Its primary candidate is treatment for Cytomegalovirus (CMV). The technology utilizes a "self targeting capability", which takes place in the natural defense mechanism of the specific disease, to target and kill infected cells. Its platform technology can be utilized to target numerous infectious diseases. The company was founded by Thomas Nitschke Kledal l in 2007 and is headquartered in Lyngby, Denmark. | Director/Board Member | - |
Ausbildung von Christian Ellebæk Elling
University of Copenhagen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IO BIOTECH, INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
7TM A/S
7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Health Technology |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
Inagen ApS
Inagen ApS Miscellaneous Commercial ServicesCommercial Services Inagen ApS is a holding company that develops novel biopharmaceuticals for anti-viral treatment opportunities. Its primary candidate is treatment for Cytomegalovirus (CMV). The technology utilizes a "self targeting capability", which takes place in the natural defense mechanism of the specific disease, to target and kill infected cells. Its platform technology can be utilized to target numerous infectious diseases. The company was founded by Thomas Nitschke Kledal l in 2007 and is headquartered in Lyngby, Denmark. | Commercial Services |
Lundbeckfonden Emerge
Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark. | Finance |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Health Technology |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Health Technology |
Insusense ApS
Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
AFYX Therapeutics AS
AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Commercial Services |